M&A
This page lets you merge the Gilead P&L with another company to see the potential impact of M&A.
Synergies are modelled by default as 10%/15%/20% of the acquisition SGA+RND costs in years 1/2/3+ starting from 2025 and taxed at Gilead standalone rates. You can choose your own numbers.
Everything is modelled in USD at current FX rates.
Target Company:
Loading...
{{$select.selected.name}}
{{company.name}}
No matches found...
Custom Synergies ($m):
This feature is only available to DRUGANALYST subscribers
